User: Guest

BIPOLAR DISORDER THERAPEUTICS

Global Market Trajectory & Analytics

MCP-6202

VALIDATED EXECUTIVE ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

6988

Interactions with Platform & by Email *

INTERACTIONS

1118

Unique # Participated *

PARTICIPANTS

212

Responses Validated *

VALIDATIONS

96

* Login to view program details and full enterprise executive list.


  •  DATE

    JULY 2020

  •  TABLES

    117

  •  PAGES

    200

  •  EDITION

    18

  •  PRICE

    USD $5450


COVID-19 IMPACT SURVEY
Amid the COVID-19 crisis, the global market for Bipolar Disorder Therapeutics estimated at US$5 Billion in the year 2020, is projected to reach a revised size of US$5.4 Billion by 2027, growing at a CAGR of 1% over the analysis period 2020-2027. Mood Stabilizers, one of the segments analyzed in the report, is projected to record a 0.3% CAGR and reach US$560.8 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Anticonvulsants segment is readjusted to a revised 0.8% CAGR for the next 7-year period.
The Bipolar Disorder Therapeutics market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$992.9 Million by the year 2027 trailing a CAGR of 2.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at -0.1% and 0.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 0.2% CAGR.
In the global Antipsychotic Drugs segment, USA, Canada, Japan, China and Europe will drive the 0.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.7 Billion in the year 2020 will reach a projected size of US$1.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$698.3 Million by the year 2027, while Latin America will expand at a 1.7% CAGR through the analysis period. We bring years of research experience to this 18th edition of our report. The 200-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others, AbbVie, Inc.; Allergan PLC; AstraZeneca PLC; Eli Lilly and Company; GlaxoSmithKline PLC; Janssen Pharmaceuticals; Novartis International AG; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.
» Drug Class (Mood Stabilizers, Anticonvulsants, Antipsychotic Drugs, Antidepressant Drugs, and Anti-anxiety Drugs)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

  • A: 
    ACTIVE CLIENT
  • B: 
    INACTIVE CLIENT
  • C: 
    ACTIVE PANELIST
  • D: 
    INACTIVE PANELIST
  • E: 
    OPT-INS
  
REPORT INDEX PROJECT COMPENDIUM * EXPERT PANEL